Indivior reaches agreement with US state AGs over Suboxone monopoly

5 June 2023

More than three dozen state-level enforcers reached a $102.5 million deal with Indivior (LSE: INDV) to resolve claims that the drugmaker monopolized the market for the opioid addiction treatment Suboxone (buprenorphine) ahead of a looming September trial.

The agreement marks the comprehensive resolution of the states’ claims against the company in the multi-district litigation (MDL). It will become final once entered by the US District Court for the Eastern District of Pennsylvania, said Indivior, whose shares were up 10.9% at 1,636 pence mid-morning today. The settlement finalized and announced on Friday puts an end to roughly seven years of legal wrangling.

The settlement amount is in line with the original provision of $290 million for the overall MDL. Once the Agreement is entered by the Court, the settlement amount will be recorded against the $290 million provision. Payment is expected to be made in June of 2023, funded from the Company’s existing cash.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK